AVITA Medical (RCEL) Common Equity (2018 - 2025)

AVITA Medical (RCEL) has 8 years of Common Equity data on file, last reported at -$16.6 million in Q4 2025.

• For the quarter ending Q4 2025, Common Equity fell 470.08% year-over-year to -$16.6 million; the trailing twelve-month figure through Dec 2025 stood at -$16.6 million (down 470.08% YoY), and the FY2025 full-year result was -$16.6 million, down 470.08% from the prior year.
• Common Equity for Q4 2025 stood at -$16.6 million, down from -$6.7 million in the prior quarter.
• Across five years, Common Equity topped out at $118.9 million in Q1 2021 and bottomed at -$16.6 million in Q4 2025.
• The 5-year median for Common Equity is $65.8 million (2023), against an average of $55.2 million.
• The widest annual swing landed in 2021, when Common Equity soared 75.55%; it then tumbled 470.08% in 2025.
• A 5-year view of Common Equity shows it stood at $104.6 million in 2021, then dropped by 19.01% to $84.7 million in 2022, then slumped by 42.11% to $49.1 million in 2023, then sank by 90.83% to $4.5 million in 2024, then sank by 470.08% to -$16.6 million in 2025.
• The last three Common Equity figures came in at -$16.6 million (Q4 2025), -$6.7 million (Q3 2025), and -$12.9 million (Q2 2025), per Business Quant data.

Peer Comparison